Genprex (NASDAQ:GNPX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Genprex (NASDAQ:GNPX) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Genprex Stock Down 3.6%

NASDAQ GNPX opened at $0.83 on Friday. The stock’s 50-day simple moving average is $1.42 and its two-hundred day simple moving average is $2.40. Genprex has a twelve month low of $0.81 and a twelve month high of $55.00. The company has a market capitalization of $8.79 million, a price-to-earnings ratio of -0.03 and a beta of -0.94.

Genprex (NASDAQ:GNPX) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Mayflower Financial Advisors LLC bought a new position in shares of Genprex during the first quarter valued at about $36,000. Manchester Financial Inc. bought a new position in shares of Genprex during the first quarter valued at about $36,000. Finally, Susquehanna International Group LLP grew its stake in shares of Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after buying an additional 35,661 shares during the last quarter. 14.05% of the stock is owned by institutional investors.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.